By Iain Gilbert
Date: Tuesday 07 Oct 2025
(Sharecast News) - Cell and gene therapy outfit Oxford Biomedica said on Tuesday that it had agreed to acquire a viral vector manufacturing site in Rockville, Maryland, from ABL for $60m in cash, expanding its US footprint and strengthening its contract development and manufacturing offering.
By Abigail Townsend
Date: Tuesday 23 Sep 2025
(Sharecast News) - Oxford Biomedica reiterated full-year guidance on Tuesday, after the biopharma saw strong demand throughout the first half and trimmed losses.
By Iain Gilbert
Date: Tuesday 26 Aug 2025
(Sharecast News) - Analysts at RBC Capital Markets hiked their target price on gene and cell therapy firm OXB from 800p to 930p on Tuesday following its recent oversubscribed £60m equity funding and revenue guidance reiteration.
Currency | UK Pounds |
Share Price | 617.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 653.00 |
52 Week Low | 232.50 |
Volume | 0 |
Shares Issued | 120.21m |
Market Cap | £741.68m |
RiskGrade | 125 |
Value |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Price Trend |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Income | ![]() |
---|
Growth |
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Strong Buy | 4 |
Buy | 2 |
Neutral | 4 |
Sell | 0 |
Strong Sell | 0 |
Total | 10 |
No dividends found |
Chair | Roch Doliveux |
CEO | Frank Mathias |
CFO | Lucinda (Lucy) Crabtree |
You are here: research